Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673829 | 0.89 | JAK2 (0.51) | JAK2KCNH2JAK3RBP4 | |
| SCHEMBL3510587 | 0.85 | JAK2 (0.62) | JAK2KCNH2JAK3JAK1 | |
| SCHEMBL1673756 | 0.84 | JAK2 (0.56) | JAK2KCNH2JAK3 | |
| SCHEMBL1673832 | 0.84 | JAK2 (0.55) | JAK2KCNH2JAK3 | |
| SCHEMBL1673820 | 0.84 | JAK2 (0.54) | JAK2KCNH2JAK3 | |
| SCHEMBL1674142 | 0.83 | JAK2 (0.56) | JAK2KCNH2JAK3 | |
| SCHEMBL1673908 | 0.83 | JAK2 (0.50) | JAK2KCNH2JAK3 | |
| SCHEMBL1674184 | 0.83 | JAK2 (0.53) | JAK2KCNH2JAK3 | |
| SCHEMBL1673910 | 0.82 | JAK2 (0.51) | JAK2KCNH2JAK3 | |
| SCHEMBL1673840 | 0.81 | JAK2 (0.49) | JAK2KCNH2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | claimed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | claimed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2299816-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344144-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082136-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885KCNH2 1568/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.